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The endothelial barrier function requires the adhesive activity of VE-cadherin and claudin-
5, two key components of adherens and tight endothelial junctions, respectively. Emerging 
evidence that VE-cadherin controls claudin-5 expression by preventing the nuclear 
accumulation of FoxO1 and β-catenin, which repress the claudin-5 promoter, provides a 
crosstalk between these endothelial junctional structures. 
 
The formation of adhesive structures 
between adjacent cells, including adherens 
and tight junctions, contribute to the 
establishment of cell polarity, differentiation 
and survival, and is ultimately required for 
the maintenance of the tissue integrity. 
Cadherins, the main constituent of the 
adherens junctions, belong to a conserved 
family of adhesion molecules that provide a 
molecular bond between cells and link the 
plasma membrane with the intracellular 
actin cytoskeleton through catenin family 
proteins1. Tight junctions form a dense ultra-
structure organization, observable by 
electron microscopy, which involves 
numerous adhesive molecules, including 
occludin, junctional adhesion molecules 
(JAMs), and the claudin family of tetraspan 
transmembrane proteins, as well as and 
intracellular adapters, such as ZO-1 and ZO-
22. Whereas in epithelial cells, tight 
junctions are often located apically with 
respect to adherens junctions, in other cells, 
such as in endothelial cells, the adherens and 
tight junctions are intermingled throughout 
cell-cell contact areas3. The formation, 
maintenance, and remodelling of the 
intercellular contacts requires a functional 
interaction between these two adhesive 
structures. For example, the barrier function 
of the endothelium requires the adhesive 
activity of VE-cadherin and claudin-5, 
which are key components of the adherens 
and tight endothelial junctions, respectively. 
Surprisingly, this functional relationship 
involves also the direct control of the 
expression of claudin-5 by VE-cadherin. 
Indeed, as shown on page xxx of this issue 
by Taddei et al, VE-cadherin-mediated 
adhesion enables claudin-5 expression in 
endothelial cells by preventing the nuclear 
accumulation of two transcriptional 
regulators, FoxO1 and β-catenin, which 
repress claudin-5 expression when VE-
cadherin is absent or non-functional (Fig. 1). 
These findings clearly place VE-cadherin 
upstream of claudin-5 in the establishment, 
maturation and maintenance of endothelial 
cell-cell junctions and further suggest that 
any changes in VE-cadherin adhesive 
properties will impact at multiple levels on 
the endothelial barrier function. 
At the molecular level, Taddei et al. 
observed that VE-cadherin adhesion triggers 
a sustained activation of the PI-3 
kinase/AKT pathway, and the subsequent 
phosphorylation of FoxO1, a forkhead 
repressor transcription factor, which results 
in its cytosolic localization, thus preventing 
FoxO1 binding to its DNA targets within the 
nuclear compartment. In the absence of VE-
cadherin at the cell surface, non-
phosphorylated FoxO1 constitutively 
accumulates within the nucleus thereby 
repressing the claudin-5 promoter by acting 
directly on two FoxO1 response elements 
(Fig. 1). Strikingly, β-catenin is required for 
FoxO1 repression of claudin-5 gene 
expression, most likely through the 
stabilization of FoxO1 interactions to its 
DNA recognition sites. This depends on the 
T-cell factor (TCF), which is constitutively 
associated to the claudin-5 promoter. Further 
work is still required to understand fully 
how FoxO1 phosphorylation modulates its 
localization, interactions with β-catenin and 
TCF, and its transcriptional repressive 
activity. 
The role of cadherins in the control of 
gene expression has been often associated to 
their negative effect on the canonical Wnt-
initiated pathway, by a mechanism that 
involves the retention of β-catenin at the 
plasma membrane upon binding to clustered 
cadherins, which therefore limits the pool of 
free β-catenin available for nuclear 
shuttling4. The mechanism identified here in 
endothelial cells is quite reminiscent to that 
recently described in neuronal cells, in 
which Slit stimulation of its receptor, Robo, 
triggers the rapid loss of N-cadherin 
dependent adhesion, which leads to the 
release of β-catenin from adhesion 
complexes and its nuclear accumulation and 
activation of β-catenin/TCF target genes5. In 
light of these studies, it will be intriguing to 
determine whether FoxO1 might also 
participate in the Slit/Robo long-term 
remodelling of cell adhesion in axon 
guidance, and how the partition of β-catenin 
between FoxO and TCF is integrated in 
response to canonical Wnt signalling. In this 
regard, β-catenin’s interaction with FoxO 
has been proposed to compete with TCF/β-
catenin-dependent activation of canonical 
Wnt-target genes6, while Taddei et al. 
suggest that TCF is required for β-
catenin/FoxO1 stabilization on the claudin-5 
promoter. This raises the question as to 
whether Wnt-regulated target genes are also 
affected by VE-cadherin adhesion, either 
directly by β-catenin trapping, and/or by 
FoxO competition. While VE-cadherin can 
be considered as a multifunctional adhesion 
receptor modulating endothelial biology, the 
emerging picture is that VE-cadherin may 
also dictate endothelial cell fate through the 
regulation of intracellular signalling 
circuitries controlling gene transcription via 
multiple DNA-binding proteins including, at 
least, β-catenin, TCF and FoxO1. 
The nature of the adhesion molecules, 
such as VE-cadherin and claudin-5, 
distinguish endothelial junctions, as their 
pattern of expression is highly restricted to 
the endothelial lineage and their 
organization is quite distinct from more 
common junctions, such as those found in 
epithelial cells3. Their functions are non-
redundant since, for instance, claudin-5 is 
the major claudin identified in normal 
endothelial cells while multiple claudins can 
be found at the surface of epithelial cells. 
Interestingly, while claudin-5 knockout mice 
develop normally but have a defective blood 
brain barrier function and die shortly after 
birth7, VE-cadherin knockout mice are 
embryonic lethal and exhibit multiple severe 
defects during developmental angiogenesis 
8, suggesting that VE-cadherin function may 
go far beyond promoting cell-cell adhesion. 
For example, VE-cadherin can modulate 
VEGF receptor signalling, which transduces 
the pro-angiogenic and pro-permeability 
effects of VEGF8. Indeed, many of the 
biological responses attributed to VE-
cadherin appear intimately linked to VEGF 
signalling9. The work by Taddei et al. 
identifies a unique mechanism by which 
VE-cadherin can control claudin-5 
expression, independently of VEGF/VEGF 
receptor downstream signalling, as blocking 
either VEGF or the activity of its receptor 
does not alter VE-cadherin control over 
claudin-5 gene expression.  The molecular 
mechanism reported here supports a 
permissive role for VE-cadherin clustering 
on claudin-5 expression, and one can 
envision that VE-cadherin might act as key 
regulator of endothelial cell lineage, as 
ultimately claudin-5 expression is restricted 
to VE-cadherin expressing cells. However, 
more studies are required now to fully 
understand whether VE-cadherin can 
orchestrate the activation of an endothelial 
maturation program and/or the repression of 
a non-endothelial phenotype.  
In addition to angiogenesis, there is a 
plethora of physiological and pathological 
conditions where the endothelial barrier 
integrity is compromised. Hierarchically, 
VE-cadherin is major in controlling the 
endothelial barrier function. For example, 
VE-cadherin endocytosis and uncoupling 
from catenin-associated proteins have been 
proposed to collectively contribute to the 
disruption of endothelial cell-cell junctions 
in response to VEGF10, 11. In light of the 
study published in page xxx of this issue, 
inhibition of VE-cadherin expression level, 
its adhesive ability, or its plasma membrane 
availability might provoke β-catenin and 
FoxO1 nuclear accumulation, and therefore 
the repression of claudin-5 transcription 
(Fig. 1). Thus, while the acute VEGF 
stimulation could induce an increase in 
vascular permeability by a reversible 
disruption of VE-cadherin adhesion and the 
subsequent disorganization of the tight 
junctions10, the chronic exposure to VEGF 
or other pro-permeability factors might 
affect severely the endothelial barrier, as the 
turnover and the expression of claudin-5 
could be compromised in the absence of 
functional VE-cadherin adhesion. The 
regulation of claudin-5 expression by VE-
cadherin points to an intimate crosstalk 
between tight and adherens junctions. 
However, this crosstalk is bidirectional since 
tight junctional molecules, such as JAMs 
may regulate cadherin-mediated adhesion in 
endothelial cells12. 
Beside VEGF, reactive oxygen species 
can increase vascular permeability through a 
Rac-dependent mechanism, associated with 
a loss of endothelial cell-cell junctions13. 
Interestingly, recent work in C. elegans 
suggests that oxygen stress signalling 
depends on a functional interaction between 
FoxO and β-catenin14. The novel findings 
reported on page xxx allow us to speculate 
that reactive oxygen species might impact 
endothelial biology by an early action on 
VE-cadherin adhesion through a Rac 
signalling nexus and later by downregulating 
claudin-5 expression (Fig. 1). Overall, this 
two-pronged control of endothelial junctions 
by VE-cadherin function may contribute to 
the pathological disruption of the vascular 
wall, which is observed in variety of 
diseases such as in tumour-induced 
angiogenesis, stroke, myocardial infarction, 
inflammation, allergy, and macular 
degeneration, to name a few. It is also 
noteworthy that the severe blood brain 
barrier phenotype of claudin-5 knockout 
mice has elicited the attention on claudin-5 
in search for treatments for diseases 
associated with aberrant blood brain barrier 
function, or to enhance the efficiency of 
drug delivery to the brain7. The signalling 
pathway characterized here may now offer 
the opportunity to reconsider VE-cadherin as 
a molecular target for the treatment of 
central nervous system diseases. For 
instance, brain stroke morbidity is associated 
with neural cell damage caused by the 
breakdown of the blood brain barrier, and 
the subsequent exudation of plasma 
components and oedema. In this regard, 
blocking VEGF pro-permeability signalling 
had successfully permitted to limit the size 
of the lesion in mouse models for brain 
ischemia15. We can now anticipate that 
restoring VE-cadherin adhesion and function 
might not only reduce vascular leakage, 
perhaps more effectively than VEGF 
antagonists, as it may also help rescuing the 
blood brain barrier function by providing a 
positive feedback on claudin-5 expression.   
 Vascular leakage and loss of the 
endothelial barrier integrity is a hallmark of 
pathological angiogenesis. Substantial 
progresses had been recently made in 
understanding the molecular mechanisms 
regulating endothelial cell-cell junctions. 
The direct impact of VE-cadherin on the 
regulation of expression of the tight junction 
protein claudin-5 provides now a further 
rationale for the development of therapeutic 
approaches targeting VE-cadherin and its 
downstream molecules for vascular 
“normalization” in many human diseases 
that involve aberrant angiogenesis and 
vascular leakage.  
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Figure 1. VE-cadherin adhesion can unlock claudin-5
transcriptional repression.
Endothelial cells express functional VE-cadherin in quiescent
conditions, and VE-cadherin adhesion can trigger claudin-5
expression by preventing FoxO1 and β-catenin localization in the
nucleus, where they could repress claudin-5 transcription. This
mechanism, together with the organization of VE-cadherin and
claudin-5 adhesions and their crosstalk through Z0-1, controls
the integrity of the endothelial barrier. Upon a pro-permeability
factor, such as VEGF or reactive oxygen species (ROS), VE-
cadherin adhesion is destabilized and both non-phosphorylated
FoxO1 and β-catenin accumulated in the nucleus where they
bind to the claudin-5 promoter and inhibit its transcription,
therefore amplifying the lost of endothelial cell-cell junctions
initiated by VE-cadherin internalization.
disruption
of adherens junction
 
 
